Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Samsung Bioepis Co. Ltd.

Division of Samsung Electronics Co. Ltd.
www.samsungbioepis.com

Latest From Samsung Bioepis Co. Ltd.

Biosimilar Sponsors Are Not Liable Under State Law For Declining Patent Dance

US Federal Circuit finds in Amgen v. Sandoz that the BPCIA preempts innovator companies from seeking penalties under state law against a biosimilar sponsor that does not engage in the 'patent dance.'

BioPharmaceutical Policy

Pfizer's Infliximab Biosimilar Approved In US But Won't Launch Against Inflectra

Ixifi (infliximab-qbtx), which references Janssen's Remicade, marks first US approval of a biosimilar developed entirely by Pfizer; big pharma says it is not currently planning to launch Ixifi because it remains "committed" to marketing Celltrion's Inflectra.

Approvals Biosimilars

Korea 2017 Review: Biosimilar Advances, R&D Progress Restore Confidence

Strong global advances in biosimilars and progress in new drug development as well as clampdowns on illegal rebate payments have dominated headlines in South Korea in 2017.

Commercial South Korea

Pipeline Watch: Phase III Progress With Tecentriq, Viaskin Peanut And Capalizumab

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • South Korea
  • Parent & Subsidiaries
  • Samsung Electronics Co. Ltd.
  • Senior Management
  • Christopher Hansung Ko, PhD, CEO
  • Contact Info
  • Samsung Bioepis Co. Ltd.
    Phone: 32 455 3114
    107, Cheomdan-daero
    Yeonsu-Gu
    Incheon, 406-840
    South Korea
Advertisement
Advertisement
UsernamePublicRestriction

Register